Plinabulin
- Generic Name
- Plinabulin
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N4O2
- CAS Number
- 714272-27-2
- Unique Ingredient Identifier
- 986FY7F8XR
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
BeyondSpring's Plinabulin Shows Promising Survival Benefits in Lung Cancer and Strategic Advances in Protein Degradation
• BeyondSpring's Plinabulin demonstrated statistically significant survival benefits in second and third-line non-small cell lung cancer (EGFR wild-type) patients, with results published in The Lancet Respiratory Medicine.
• Phase 2 studies show Plinabulin's potential to resensitize tumors that have progressed on PD-1/PD-L1 inhibitors in metastatic NSCLC, addressing a significant unmet need as 60% of patients develop resistance to checkpoint inhibitors.
• SEED Therapeutics, co-founded by BeyondSpring, secured a research collaboration with Eisai worth up to $1.5 billion and received FDA Rare Pediatric Disease and Orphan Drug Designations for its RBM39 degrader.
Plinabulin Combination Shows Tolerability in Recurrent Small Cell Lung Cancer Trial
• A Phase I/II trial evaluated plinabulin with nivolumab and ipilimumab in recurrent small cell lung cancer (SCLC) patients, focusing on safety and efficacy.
• The combination was found to be tolerable, with a recommended Phase 2 dose of plinabulin at 30 mg/m², though common adverse events included vomiting and nausea.
• The trial did not meet its primary endpoint of a median progression-free survival of 3.5 months, but some patients exhibited durable responses to the treatment.
• The rate of grade 3 or higher immune-related adverse events was lower than anticipated, suggesting a potentially manageable safety profile for the combination therapy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath